High-dose intensity cyclophosphamide, epidoxorubicin, vincristine and prednisone by shortened intervals and granulocyte colony-stimulating factor in non Hodgkin's lymphoma: A phase II study

P. Pronzato, R. Lionetto, F. Botto, F. Pensa, A. Tognoni

Research output: Contribution to journalArticlepeer-review

Abstract

Twenty patients with non-Hodgkin's lymphoma were treated with a combination of cyclophosphamide (750 mg m -2, day 1), epidoxorubicin (60 mg m -2, day 1), vincristine (1.4 mg m -2, day 1) and prednisone (100 mg m -2, days 1-5) every 14 days. Shortening of intervals was associated with the prophylactic employment of granulocyte colony-stimulating factor (G-CSF; specifically filgrastim) administered at a dose of 300 μg subcutaneously from day 6 to day 11. The ratio between actually delivered dose intensity and planned dose intensity was 1.0 in 18 out the 20 patients. Toxicity was acceptable; response rate and survival are in the expected range. The present study demonstrated the feasibility of acceleration of chemotherapy cycles to obtain dose intensification in non-Hodgkin's lymphoma.

Original languageEnglish
Pages (from-to)777-780
Number of pages4
JournalBritish Journal of Cancer
Volume78
Issue number6
Publication statusPublished - 1998

Keywords

  • Dose intensity
  • Granulocyte colony-stimulating factor
  • Non-Hodgkin's lymphoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'High-dose intensity cyclophosphamide, epidoxorubicin, vincristine and prednisone by shortened intervals and granulocyte colony-stimulating factor in non Hodgkin's lymphoma: A phase II study'. Together they form a unique fingerprint.

Cite this